Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5098890A · kind A · utility
139Cited by
1References
44Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 1989 |
| Grant date | Mar 24, 1992 |
| Priority date | — |
| Expiry date | Oct 27, 2009 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/1135
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene. These "antisense" oligonucleotides are hybridizable to the c-myb mRNA transcript. Such oligonucleotides are useful in treating hematologic neoplasms and in inducing immunosuppression. They are particularly useful as bone marrow purging agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.